References
- Tolia VN, Patrick SW, Bennett MM, et al. Increasing incidence of the neonatal abstinence syndrome in U.S. Neonatal ICUs. N Engl J Med. 2015;372:1–9.
- Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320–2331.
- Logan B, Brown M, Hayes M. Neonatal abstinence syndrome: treatment and pediatric outcomes. Clin Obstet Gynecol. 2013;56(1):186–192.
- Seligman NS, Salva N, Hayes EJ, et al. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol. 2008;199(4):396.e1–396.e7.
- Mack G, Thomas D, Giles W, et al. Methadone levels and neonatal withdrawal. J Paediatr Child Health. 1991;27(2):96–100.
- Nanovskaya TN, Deshmukh SV, Nekhayeva IA, et al. Methadone metabolism by human placenta. Biochem Pharmacol. 2004;68(3):583–591.
- Deshmukh SV, Nanovskaya TN, Ahmed MS. Aromatase is the major enzyme metabolizing buprenorphine in human placenta. J Pharmacol Exp Ther. 2003;306(3):1099–1105.
- Townsel C, Covault J, Hussain N, et al. Placental aromatase expression decreased in severe neonatal opioid withdrawal syndrome. J Matern Fetal Neonatal Med. 2021;34(5):670–676.
- Rubinchik-Stern M, Eyal S. Drug interactions at the human placenta: what is the evidence? Front Pharmacol. 2012;3:126.
- Walker N, Filis P, Soffientini U, et al. Placental transporter localization and expression in the human: the importance of species, sex, and gestational age differences. Biol Reprod. 2017;96(4):733–742.
- Nanovskaya T, Nekhayeva I, Karunaratne N, et al. Role of P-glycoprotein in transplacental transfer of methadone. Biochem Pharmacol. 2005;69(12):1869–1878.
- Neradugomma NK, Liao MZ, Mao Q. Buprenorphine, norbuprenorphine, R-methadone, and S-methadone upregulate BCRP/ABCG2 expression by activating aryl hydrocarbon receptor in human placental trophoblasts. Mol Pharmacol. 2017;91(3):237–249.
- Fournet-Dulguerovf N, Maclusky NJ, Leranth CZ, et al. Immunohistochemical localization of aromatase cytochrome P-450 and estradiol dehydrogenase in the syncytiotrophoblast of the human placenta. J Clin Endocrinol Metab. 1987;65(4):757–764.
- Han LW, Gao C, Mao Q. An update on expression and function of P-gp/ABCB1 and BCRP/ABCG2 in the placenta and fetus. Expert Opin Drug Metab Toxicol. 2018;14(8):817–829.
- Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17(5):1474–1481.
- Inkster SE, Brodie AMH. Immunocytochemical studies of aromatase in early and full-term human placental tissues: comparison with biochemical assays. Biol Reprod. 1989;41(5):889–898.
- Sathishkumar K, Balakrishnan M, Chinnathambi V, et al. Fetal sex-related dysregulation in testosterone production and their receptor expression in the human placenta with preeclampsia. J Perinatol. 2012;32(5):328–335.
- Mathias AA, Hitti J, Unadkat JD. P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. Am J Physiol Regul Integr Comp Physiol. 2005;289(4):R963–969.